Clinical trials
Second Line Treatment clinical trials
Below are recruiting second line treatment clinical trials, each written for real people, not researchers. We’re tracking 155 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03913819Recruiting
Standard treatment for bladder problems caused by substance abuse
This trial tests how well a set “standard” treatment plan works for people with bladder emptying problems caused by substance abuse. You might consider it if you have this specific type of bladder issue and can follow the treatment plan.
ShatinAges Any age - NCT05958875RecruitingPhase 4
Six-week medicine switch for schizophrenia after first treatment failure
This trial tests whether a more intensive medication approach for schizophrenia (or related conditions) helps people who didn’t improve on their first tried medicine. Participants will usually switch medicines and be compared against “treatment as usual.”
InnsbruckAges 18–70 - NCT06751914Recruiting
Vaccine plus standard therapy for advanced colorectal cancer
This trial tests a personalized vaccine made from your tumor's unique markers, combined with standard second-line treatment, for colorectal cancer that has grown after first treatment. It aims to see if this combination can help control the cancer better.
Nanchang, JiangxiAges 18–70 - NCT06751940Recruiting
Personalized vaccine plus standard therapy for advanced colorectal cancer
This trial tests a personalized vaccine made from your tumor's unique features, combined with a standard second-line treatment, for colorectal cancer that has worsened after the first treatment. The goal is to see if this combination can help control the cancer better than standard therapy alone.
Nanchang, JiangxiAges 18–70 - NCT06751953Recruiting
Neoantigen vaccine plus standard third-line therapy for colorectal cancer
This study tests a vaccine made from your tumor's unique proteins (neoantigens) combined with a standard third-line therapy for colorectal cancer that has worsened after two previous treatments. The goal is to see if this combination helps control the cancer better.
Nanchang, JiangxiAges 18–70 - NCT06841055RecruitingPhase 2
Pumitamig plus chemo for Stage IV lung cancer after immunotherapy
This trial tests a new investigational drug called Pumitamig (BNT327) given with chemotherapy for people with advanced non-small cell lung cancer (Stage IV) that has continued to grow after one prior treatment with immunotherapy and platinum chemotherapy. The study aims to see if this combination is safe and can help shrink the cancer.
Birmingham, AlabamaAges 18 years+ - NCT07213570RecruitingPhase 2
Second-line regorafenib for advanced RAS-mutant colorectal cancer
This trial tests regorafenib as a second-line treatment for people with advanced colorectal cancer that has a RAS mutation. It aims to see if this targeted therapy can help when the first treatment stopped working.
Naples, ItalyAges 18 years+ - NCT07320586RecruitingPhase 2
Carilizumab and chemo for advanced gastric cancer
This trial tests a combination of carilizumab (an immunotherapy) and albumin paclitaxel (a chemotherapy drug) for people with advanced stomach or gastroesophageal junction cancer that has gotten worse after first-line treatment. It aims to see if this second-line option can help control the cancer.
Jinan, ShandongAges 18–75 - NCT07389876Recruiting
Second-line treatment for advanced stomach cancer with nab-paclitaxel
This trial tests a new chemotherapy combination for patients with advanced stomach cancer that has worsened after initial treatment. It aims to find a better second-line option using a drug called nab-paclitaxel.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06751966Recruiting
Peptide vaccine plus standard therapy for advanced colorectal cancer
This trial tests a personalized peptide vaccine (based on your tumor's unique markers) combined with standard third-line therapy for colorectal cancer that has progressed after two prior treatments. The goal is to see if adding the vaccine can help control the cancer better.
Nanchang, JiangxiAges 18–70 - NCT05603104RecruitingPhase 3
Medication intensification after first treatment failure in mood and psychosis
This Phase 3 study tests a stronger medication approach after your first current treatment hasn’t worked well enough. It targets people with schizophrenia, major depressive disorder, or bipolar depression who still have significant symptoms and life impact.
Ramat GanAges 18–70 - NCT05973851RecruitingPhase 3
Six-week medicine boost for depression after first treatment failure
This study tests a more intensive antidepressant medicine approach for people whose first tried treatment didn’t work well enough. It compares the intensified treatment with usual care, aiming to improve depression symptoms and daily functioning.
InnsbruckAges 18–65 - NCT07288034RecruitingPhase 2
Immunotherapy biomarkers for advanced lung cancer
This study looks at blood and tissue biomarkers to predict how well immunotherapy (with or without chemotherapy) works for advanced non-small cell lung cancer. It also helps decide the best second treatment if the first one stops working.
Goodyear, ArizonaAges 18 years+ - NCT06394674RecruitingPhase 2
High-dose furmonertinib for lung cancer after osimertinib stops working
This trial tests a higher dose of a targeted therapy called furmonertinib for people with advanced lung cancer that has stopped responding to a previous drug called osimertinib. It may help if you have a certain EGFR mutation and your cancer has grown outside the brain.
ShanghaiAges 18–75 - NCT06959589Enrolling by invitationPhase 2
Combination therapy for KRAS G12C mutated colorectal cancer
This trial tests a new drug combination (IBI351, cetuximab, and FOLFIRI) as first treatment or as a second treatment after standard chemotherapy for people with KRAS G12C mutated colorectal cancer that has spread. The goal is to see if it works well and is safe.
Hangzhou, ZhejiangAges 18–75 - NCT06446154RecruitingPhase 2
Fruquintinib after immunotherapy for advanced liver cancer
This trial tests a new drug called fruquintinib for people with advanced liver cancer who have already tried immunotherapy. It may help shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18 years+ - NCT05057468RecruitingPhase 3
Second-line treatment for warm autoimmune anemia
This Phase 3 study tests a second-line treatment for adults with warm autoimmune hemolytic anemia whose disease is not controlled with steroids, who cannot tolerate steroids, or who decline standard treatment. It aims to improve anemia and reduce ongoing red blood cell destruction caused by the immune system.
Asyut, Asyut GovernorateAges 18 years+ - NCT06063018RecruitingPhase 2
Testing RC48 and Tislelizumab for recurrent cervical cancer with HER2
This trial tests a combination of two drugs, RC48 and Tislelizumab, for people with recurrent cervical cancer whose tumors have a protein called HER2. The goal is to see if this treatment can help when previous therapy has stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT06751901RecruitingPhase 2
Vaccine, immunotherapy, and radiation for advanced lung cancer
This trial tests a combination of a personalized peptide vaccine, an immunotherapy drug (PD-1 inhibitor), and radiation for people with advanced non-small cell lung cancer whose disease has gotten worse after at least two standard treatments. It aims to see if this triple therapy can help control the cancer.
Nanchang, JiangxiAges 18–70 - NCT06406426RecruitingPhase 2
New drug combo for advanced stomach cancer after first treatment fails
This trial tests a combination of three drugs—cadonilimab, fruquintinib, and albumin-bound paclitaxel—as a second treatment for advanced stomach cancer. It may be an option if your first treatment stopped working and you have not had certain types of prior therapy.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06751849RecruitingPhase 2
Vaccine, immunotherapy, and radiation for advanced lung cancer
This trial tests a combination of a personalized cancer vaccine, an immunotherapy drug (PD-1 inhibitor), and radiation therapy for people with advanced non-small cell lung cancer that has gotten worse after at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow cancer growth.
Nanchang, JiangxiAges 18–70 - NCT07550673RecruitingPhase 4
Upadacitinib vs. Infliximab for Severe Ulcerative Colitis
This study compares two medications—upadacitinib and infliximab—as second-line treatments for acute severe ulcerative colitis (a serious flare of inflammatory bowel disease). The trial will help doctors understand which treatment works better when standard first-line therapy hasn't controlled the inflammation.
Ankang, ShaanxiAges 18–85 - NCT06629584RecruitingPhase 2
Asciminib for second-line chronic phase CML
This study tests a pill called asciminib for people with chronic phase CML whose first targeted therapy didn't work or caused side effects. The goal is to see if asciminib can better control the disease with fewer problems.
Houston, TexasAges 18 years+ - NCT06447727Recruiting
Y-90 beads plus chemo for liver-only colorectal cancer
This trial tests whether adding radioactive Y-90 microspheres (tiny beads that deliver radiation directly to liver tumors) to standard chemo (FOLFIRI and bevacizumab) can help people with advanced colorectal cancer that has spread only to one lobe of the liver, when the first treatment stopped working. The goal is to slow down tumor growth.
Nanjing, JiangsuAges 18–75
Hear when a new Second Line Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for second line treatment?
- Yes. Clin2 currently lists 155 recruiting second line treatment studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a second line treatment trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a second line treatment trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.